Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($)		3 Months Ended	9 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Carrying value of investments	$ 0		$ 9,976,984
Inventory reserve	900,000		$ 1,000,000
Cash discount to incentive for prompt payment				2.00%
Teva [Member]
Summary Of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent			50.00%
OTREXUP [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional revenue recognized, not previously recognized		$ 1,297,054
Related product costs recognized		$ 254,425
Revenue Recognition, decrease in net loss			$ 1,042,629
Estimated product returns reserve	0		650,000
Product sales allowances	$ 1,540,488		$ 1,986,553
OTREXUP [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, decrease in net loss per share			$ 0.01